Corpus overview


MeSH Disease

COVID-19 (489)

Fever (101)

Pneumonia (94)

Death (80)

Hypertension (72)

HGNC Genes

SARS-CoV-2 proteins

ProteinN (7)

ProteinS (2)

ORF1ab (1)

ProteinS1 (1)


SARS-CoV-2 Proteins
    displaying 21 - 30 records in total 498
    records per page

    The Prognostic Value of Myocardial Injury MESHD in COVID-19 MESHD Patients and Associated Characteristics

    Authors: jian he; Bicheng Zhang; Quan Zhou; Wenjing Yang; Jing Xu; Tingting Liu; Haijun Zhang; Zhiyong Wu; Dong Li; Qing Zhou; Jie Yan; Cuizhen Zhang; Robert G. Weiss; Guanshu Liu; Zhongzhao Teng; Arlene Sirajuddin; Haiyan Qian; Shihua Zhao; Andrew E. Arai; Minjie Lu; Xiaoyang Zhou

    doi:10.21203/ Date: 2021-02-17 Source: ResearchSquare

    Background: Since December 2019, Coronavirus disease 2019 MESHD ( COVID-19 MESHD) has emerged as an international pandemic. COVID-19 MESHD patients with myocardial injury MESHD might need special attention. However, understanding on this aspect remains unclear. This study aimed to illustrate clinical characteristics and the prognostic value of myocardial injury MESHD to COVID-19 MESHD patients. Methods: This retrospective, single-center study finally included 304 hospitalized COVID-19 MESHD cases confirmed by real-time RT-PCR from January 11 to March 25, 2020. Myocardial injury MESHD was determined by serum high-sensitivity troponin I (Hs-TnI). The primary endpoint was COVID-19 MESHD associated mortality. Results: Of 304 COVID-19 MESHD patients (median age, 65 years; 52.6% males), 88 patients (27.3%) died (61 patients with myocardial injury MESHD, 27 patients without myocardial injury MESHD on admission). COVID-19 MESHD patients with myocardial injury MESHD had more comorbidities ( hypertension MESHD, chronic obstructive pulmonary disease MESHD, cardiovascular disease MESHD, and cerebrovascular disease MESHD); lower lymphocyte counts, higher C-reactive protein HGNC ( CRP HGNC, median, 84.9 vs 28.5 mg/L, p<0.001), procalcitonin levels (median, 0.29 vs 0.06 ng/ml, p<0.001), inflammatory and immune response markers; more frequent need for noninvasive ventilation, invasive mechanical ventilation; and was associated with higher mortality incidence (hazard ratio, HR=7.02, 95% confidence interval, CI, 4.45-11.08, p<0.001) than those without myocardial injury MESHD. Myocardial injury MESHD (HR=4.55, 95% CI, 2.49-8.31, p<0.001), senior age, CRP HGNC levels, and novel coronavirus pneumonia MESHD ( NCP PROTEIN) types on admission were independent predictors to mortality in COVID-19 MESHD patients. Conclusions: COVID patients with myocardial injury MESHD on admission is associated with more severe clinical presentation and biomarkers. Myocardial injury MESHD and higher HsTNI are both strongest independent predictors to COVID related mortality after adjusting confounding factors. In addition, senior age, CRP HGNC levels and NCP PROTEIN types are also associated with mortality. Trial registration: Not applicable.

    Development and internal verification of the hospitalization risk score to triage COVID-19 MESHD patients upon admission: a multicenter nested case-control study.

    Authors: Hongbing Peng; Chao Hu; Wusheng Deng; Lingmei Huang; Baowei Luo; Xingxing Wang; Xiaodan Long; Honghui Li; Xiaoying Huang

    doi:10.21203/ Date: 2021-02-17 Source: ResearchSquare

    Background: Novel coronavirus disease 2019 MESHD( COVID-19 MESHD)has a large population base of infection, and only worsening cases required hospitalization. A hospitalization risk score of COVID-19 MESHD(HRS- COVID-19 MESHD) to identify and treat worsening patients early thus seems crucial.Method: We conducted a multicenter nested case-control study with 200 cases enrolling confirmed symptomatic COVID-19 MESHD patients from four designated hospitals before worsened. Least Absolute Shrinkage and Selection Operator(LASSO), Directed Acyclic Graph(DAG)and Change-in-Estimate(CIE) screened out independent risk factors for HRS MESHD- COVID-19 MESHD from demographic, clinical and imaging data of the cases. The HRS- COVID-19 MESHD was evaluated by the area under curve(AUC), calibration curve, decision curve and clinical impact curve; internal validation by the bootstrap-resampling(boot=1000); and through a nomogram and a network calculator to show.Results: In the nested case cohort, 50 patients reached the compound endpoint(requiring hospitalization) and 150 patients were able to avoid hospitalization. Dyspnea MESHD, incubation period, age, lymphocyte count, C-reactive protein HGNC and semi-quantitative CT scores were included in HRS- COVID-19 MESHD. The HRS- COVID-19 MESHD has good fitting( Hosmer-Lemeshow goodness MESHD,P=0.45); high discrimination(AUC 0.980,95%CI, 0.965-0.996); with excellent calibration and clinical benefits. We make a free online risk calculator (https://hospitalization-risk-score-of- covid-19 In the study, the HRS- COVID-19 MESHD based on the clinical characteristics at admission is helpful for early identification and active treatment of aggravated high-risk COVID-19 MESHD patients.

    Outcomes of COVID-19 MESHD among Patients with End Stage Renal Disease MESHD on Remdesivir

    Authors: Vijairam Selvaraj; Muhammad Baig; Kwame Dapaah-Afriyie; Arkadiy Finn; Atin Jindal; George Bayliss

    doi:10.1101/2021.02.10.21251527 Date: 2021-02-15 Source: medRxiv

    BACKGROUNDSince the beginning of the COVID-19 pandemic MESHD, there has been widespread use of remdesivir in adults and children. There is little known information about its outcomes in patients with severe renal dysfunction MESHD or end-stage renal disease MESHD who are on hemodialysis. METHODSA retrospective, multicenter study was conducted on patients with end-stage renal disease MESHD on hemodialysis that were discharged after treatment for COVID-19 MESHD between April 1st and December 31st, 2020. Primary endpoints were the length of stay, mortality, maximum oxygen requirements along with the escalation of care needing mechanical ventilation. Secondary endpoints included change in C reactive protein HGNC, d dimer levels, and disposition. RESULTSA total of 52 charts were reviewed, of which 28 met the inclusion criteria. 14 patients received remdesivir, and 14 patients did not receive remdesivir. The majority of patients were caucasian, female, with diabetes mellitus MESHD and hypertension MESHD. The mean age was 65.33 +14.14 years. All the patients in the remdesivir group received dexamethasone as compared to only 30% of patients in the non-remdesivir group. There was no significant difference in C reactive protein HGNC, d dimer levels, and disposition between the two groups. Approximately 35% of the patients died, 18% required intensive ventilation, and the mean length of stay was 12.21 days. DISCUSSIONThe study demonstrated no clinically significant difference in length of stay, maximum oxygen requirements, or mortality in COVID-19 MESHD patients with end-stage renal disease MESHD in the remdesivir group as compared to the non-remdesivir group. Further studies are needed to study the effects of remdesivir on the renal function and disease course in patients with chronic kidney disease MESHD stage 4 or 5 that are not on dialysis.

    Compassionate use of rectal Ozone (O3) in severe COVID-19 MESHD pneumonia MESHD: a case-control study.

    Authors: Marcos Edgar Fernández-Cuadros; María Jesús Albaladejo-Florín; Sandra Alava-Rabasa; Juan Gallego-Galiana; Gerardo Fabiel Pérez-Cruz; Isabel Usandizaga-Elio; Enrique Pacios; David Torres-Garcia; Daiana Peña-Lora; Luz Casique-Bocanegra; María Jesús López-Muñoz; Javier Rodríguez-de-Cía; Olga Susana Pérez-Moro

    doi:10.21203/ Date: 2021-02-11 Source: ResearchSquare

    Objectives: To evaluate effect of rectal Ozone in severe COVID-19 MESHD pneumonia MESHD and to compare to Standard-of-care (SOC). Material and Methods: In a case-control study, 14 patients with severe bilateral COVID-19 MESHD pneumonia MESHD (positive RT-PCR), treated with SOC and rectal Ozone, were evaluated before-and-after treatment and compared with SOC (14 patients) in a 10 day follow-up period. Ozone-protocol consisted of 8 sessions (1 session/day) of intra-rectal Ozone, (150mL volume, 35mg/ml concentration [5.25mg total dose]). The SOC-protocol included O 2- supply, antivirals (Remdesivir), corticosteroids (Dexamethasone/Metilprednisolone), monoclonal antibodies (Anakinra/Tocilizumab), antibiotics (Azytromicine), anticoagulants (Enoxaparine) and hyperimmune serum (if necessary). Primary outcome variables: a) clinical (O 2- saturation and O 2- supply); b) biochemical (Lymphocyte count, Fibrinogen HGNC, D-Dimer, Urea, Ferritin, LDH, IL-6 HGNC and CRP HGNC); c) radiological Taylor Scale. Secondary outcome variables: a) hospitalization length-of-stay, b) mortality-rate. Results: At baseline, Ozone/SOC-groups were not different on age, comorbidities, O 2 -saturation and O 2 -supply. Patients in Ozone-Group improved O 2- saturation and decrease O 2- supply. SOC maintained O 2- saturation and required more O 2- supply. Lymphocyte-count improved only in Ozone-group and with statistical difference (p<0.05). Biomarkers of inflammation MESHD ( Fibrinogen HGNC, D-Dimer, Urea, LDH, CRP HGNC and IL-6 HGNC) decreased in both groups, but only significantly in favor of Ozone-group (p<0.05). Ferritin showed a significant decrease in the Ozone-group but an increase on the SOC-Group. Radiological pneumonitis MESHD decreased on both groups but the decrease was only significant in the Ozone-Group (p<0.0001). Mortality and length-of-stay, although not significant, were inferior in Ozone-Group. Conclusion: Compassionate use of Rectal Ozone improved O 2 -saturation, reduced O 2 -supply, decreased inflammation MESHD biomarkers and improved Taylor’s radiological scale significantly when compared to SOC-Group. Mortality and length-of-stay was inferior in the Ozone-group, but this difference was not significant.

    The Age Again in The Eye of The Covid-19 MESHD Storm: Evidence-Based Decision Making.

    Authors: M. Carmen Martín; Aurora Jurado; Cristina Abad-Molina; Antonio Orduña; Oscar Yarce; Ana M. Navas; Vanesa Cunill; Danilo Escobar; Francisco Boix; Sergio Burillo-Sanz; María C. Vegas-Sánchez; Yesenia Jiménez-de las Pozas; Josefa Melero; Marta Aguilar; Oana Irina Sobieschi; Marcos López-Hoyos; Gonzalo Ocejo-Vinyals; David San Segundo; Delia Almeida; Silvia Medina; Luis Fernández-Pereira; Esther Vergara; Bibiana Quirant; Eva Martínez-Cáceres; Marc Boigues; Marta Alonso; Laura Esparcia-Pinedo; Celia López-Sanz; Javier Muñoz-Vico; Serafín López-Palmero; Antonio Trujillo; Paula Álvarez; Álvaro Prada; David Monzón; Jesús Ontañón; Francisco M. Marco; Sergio Mora; Ricardo Rojo; Gema González-Martínez; María T. Martínez-Saavedra; Juana Gil-Herrera; Sergi Cantenys-Molina; Manuel Hernández; Janire Perurena-Prieto; Beatriz Rodríguez-Bayona; Alba Martínez; Esther Ocaña; Juan Molina

    doi:10.21203/ Date: 2021-02-10 Source: ResearchSquare

    Background: One hundred million of contagions, more than 2 million deaths and less than one year of COVID-19 MESHD have changed our lives and our health management systems forever. Ageing is known to be one of the significant determinants for COVID-19 MESHD severity. Two main reasons underlie this: immunosenescence and age correlation with main COVID-19 MESHD comorbidities such as hypertension or dyslipidaemia MESHD. This study has two aims. The first is to obtain cut-off points for laboratory parameters that can help us in clinical decision-making. The second one is to analyse the effect of pandemic lockdown on epidemiological, clinical, and laboratory parameters concerning the severity of the COVID-19 MESHD. For these purposes, 257 of SARSCoV2 inpatients during pandemic confinement were included in this study. Moreover, 584 case records from a previously analysed series, were compared with the present study data. Results: Concerning the characteristics of lockdown series, mild cases accounted for 14.4%, 54.1% were moderate and 31.5%, severe. There were 32.5% of home contagions, 26.3% community transmissions, 22.5% nursing home contagions, and 8.8% corresponding to frontline worker contagions regarding epidemiological features. Age >60 and male sex are hereby confirmed as severity determinants. Equally, higher severity was significantly associated with higher IL6 HGNC, CRP HGNC, ferritin, LDH, and leukocyte counts, and a lower percentage of lymphocyte, CD4 HGNC and CD8 HGNC count. Comparing this cohort with a previous 584-cases series, mild cases were less than those analysed in the first moment of the pandemic and dyslipidaemia became more frequent than before. Age, lymphocyte count and LDH had similar distributions at both moments. IL-6 HGNC, CRP HGNC and LDH values above 69 pg/mL, 97 mg/L and 328 U/L respectively, as well as a CD4 HGNC T-cell count below 535 cells/μL, were the best cut-offs predicting severity since these parameters offered reliable areas under the curve. Conclusion: Age, sex and dyslipidaemia together with selected laboratory parameters on admission can help us predict COVID-19 MESHD severity and, therefore, make clinical and resource management decisions. Demographic features associated with lockdown could affect the homogeneity of the data and the robustness of the results.

    Impacts of Antioxidant Vitamins, Curry Consumption and Heavy Metal Levels on The Metabolic Syndrome MESHD With Comorbidities: A National Cross-Sectional Study

    Authors: Hai Nguyen Duc; Hojin Oh; Min-Sun Kim

    doi:10.21203/ Date: 2021-02-09 Source: ResearchSquare

    The burden of metabolic syndrome MESHD ( MetS MESHD) is increasing worldwide especially in the coronavirus disease 2019 MESHD ( COVID-19 MESHD). This phenomenon can be related to environmental, dietary, and lifestyle risk factors. We aimed to determine the association between the levels of serum heavy metals, vitamins, and curry intake, subsequently predict the risks for MetS MESHD by margin effects. Daily intake of vitamins was measured by 24-h recall was calculated using a food frequency questionnaire. Heavy metals were quantified by graphite furnace atomic absorption spectrometry, and mercury analyzer. The risk of MetS MESHD was significantly lower in the high curry consumption than in the low curry consumption, risks of Mets were reduced by 7%, 13%, 1%, and 1%, when the levels of vitamin B1, B2, B3, and C intake increased by one mg, respectively. However, risks of Mets were increased by 9%, 3%, 5%, when the levels of serum Pb, Hg, and CRP HGNC increased by one unit. The potential health benefits resulting from vitamin and curry supplementation could guard the public against the dual burden of communicable and non-communicable diseases. Further works are required to thwart risk factors related to heavy metals and determine the mechanistic dual effects of vitamins and curry in MetS MESHD.

    Galectin-3 HGNC as a potential prognostic biomarker of severe COVID-19 MESHD in SARS-CoV-2 infected MESHD patients

    Authors: Eduardo Cervantes-Alvarez; Nathaly Limon-de la Rosa; Moises Salgado-de la Mora; Paola Valdez-Sandoval; Mildred Palacios-Jimenez; Fatima Rodriguez-Alvarez; Brenda I. Vera-Maldonado; Eduardo Aguirre-Aguilar; Juan Manuel Escobar-Valderrama; Jorge Alanis-Mendizabal; Osvely Mendez-Guerrero; Farid Tejeda-Dominguez; Jiram Torres-Ruiz; Diana Gomez-Martin; Kathryn L. Colborn; David Kershenobich; Christene A. Huang; Nalu Navarro-Alvarez

    doi:10.1101/2021.02.07.21251281 Date: 2021-02-09 Source: medRxiv

    BACKGROUNDPrognostic biomarkers are needed to identify patients at high-risk for severe COVID-19 MESHD. Galectin-3 HGNC is known to drive neutrophil infiltration and release of pro-inflammatory cytokines contributing to airway inflammation MESHD. METHODSIn this prospective cohort, we assessed galectin-3 HGNC levels in 156 hospitalized patients with confirmed COVID-19 MESHD. COVID-19 MESHD patients were diagnosed as either critical (>50% lung damage MESHD) or moderate (<50% of lung damage MESHD) based on computerized tomography. Patients who required invasive mechanical ventilation (IMV) and/or died during hospitalization were categorized as having a severe outcome, and a non-severe outcome if they were discharged and none of the former occurred. RESULTSElevated serum galectin-3 HGNC was significantly higher in critical patients compared to moderate ones (35.91 {+/-} 19.37 ng/mL vs. 25 {+/-} 14.85 ng/mL, p<0.0001). Patients who progressed to a severe outcome including IMV and/or in-hospital death, presented higher galectin-3 HGNC levels (41.17 ng/mL [IQR 29.71 - 52.25] vs. 23.76 ng/mL [IQR 15.78 - 33.97] compared to those of a non-severe outcome, p<0.0001). Galectin-3 HGNC discriminated well between those with severe and non-severe outcome, with an AUC of 0.75 (95% CI 0.67 - 0.84, p<0.0001) and was found to be an independent predictor of severe outcome regardless of the percentage of lung involvement. Additionally, the combination of galectin-3 HGNC, CRP HGNC and albumin, significantly improved its individual predicting ability with an AUC 0.84 (95% CI 0.77 - 0.91, p<0.0001). CONCLUSIONCirculating galectin-3 HGNC levels can be used to predict severe outcomes in COVID-19 MESHD patients, including the requirement of mechanical ventilation and/or death MESHD, regardless of the initial severity of the disease.

    Public risk perception and coping response to COVID-19 MESHD is moderated by positive emotions: Evidence from Chinese college students

    Authors: Yongtao Gan; Qionglin Fu

    doi:10.21203/ Date: 2021-02-08 Source: ResearchSquare

    Background: People tend to develop serious psychological problems MESHD if they perceive the threat of a special disease. Seeking and contributing risk perception has laid the groundwork for studies that explore public response in the face of a health emergency, and are helpful for the understanding of students by determining how positive emotions(PE) moderates COVID-19 MESHD-related risk perception( CRP HGNC) and can further lead to an improvement in coping response to COVID-19 MESHD(CRC). We still have little knowledgeResults: There were a moderating relationship between CRP HGNC and positive-coping behavior( PCB HGNC) and moderating relationship between CRP HGNC and risk-taking behavior(RTB) through PE. Two interactive effects were identified. First, CRP HGNC was positively predicting PCB HGNC interacting with observed PE). Second, COVID-19 MESHD-related risk perception interacted with observed PE predicting risk-taking behavior(RTB)Conclusions: The current study established a moderated model to explore the influence mechanism of CRP HGNC on two categories of coping response. For public health managers, they should have different coping response behavior and addressed the moderating role of PE in the process of coping with a public health emergency. 

    Evaluation of the Effectiveness and Safety of Adding Ivermectin to Treatment in Severe COVID-19 MESHD Patients

    Authors: Nurullah Okumuş; Nese Demirtürk; Rıza Aytaç ÇETİNKAYA; Rahmet GÜNER; İsmail Yaşar Avcı; Semiha ORHAN; Petek KONYA; Bengü ŞAYLAN; Ayşegül Karalezli; Levent YAMANEL; Bircan Kayaaslan; Gülden Yılmaz; Ümit Savaşçı; Fatma ESER; Gürhan TAŞKIN

    doi:10.21203/ Date: 2021-02-08 Source: ResearchSquare

    BACKGROUND AND OBJECTIVES:An effective treatment option is not yet available for SARS-CoV2, which causes the COVID-19 pandemic MESHD and whose effects are felt more and more every day. Ivermectin is among the drugs whose effectiveness in treatment has been investigated. In this study; it was aimed to investigate the presence of gene mutations that alter ivermectin metabolism and cause toxic effects in patients with severe COVID-19 MESHD pneumonia MESHD, and to evaluate the effectiveness and safety of ivermectin use in the treatment of patients without mutation.MATERIALS AND METHODS: Patients with severe COVID19 MESHD pneumonia MESHD were included in the study, which was planned as a prospective, randomized, controlled, single-blind phase 3 study. Two groups, the study group and the control group, took part in the study. Ivermectin 200 mcg/kg/day for five days in the form of a solution prepared for enteral use added to the reference treatment protocol -hydroxychloroquine + favipiravir + azithromycin- of patients included in the study group. Patients in the control group were given only reference treatment with 3 other drugs without ivermectin. The presence of mutations was investigated by performing sequence analysis in the mdr1 HGNC/abcab1 gene with the Sanger method in patients included in the study group according to randomization. Patients with mutations were excluded from the study and ivermectin treatment was not continued. Patients were followed for 5 days after treatment. At the end of the treatment and follow-up period, clinical response and changes in laboratory parameters were evaluated.RESULTS: A total of 66 patients, 36 in the study group and 30 in the control group were included in the study. Mutations affecting ivermectin metabolism was detected in genetic tests of six (16.7%) patients in the study group and they were excluded from the study. At the end of the 5-day follow-up period, the clinical improvement rate was higher in the study group [22/30 (73.3%)] compared to the control group [16/30 (53.3%)] (p=0.10). At the end of the study, mortality developed in 6 patients (20%) in the study group and in 9 (30%) patients in the control group (p=0.37). At the end of the follow-up period, the average peripheral capillary oxygen saturation (SpO2)  values of the study and control groups were found to be 93.5% and 93.0%, respectively. Partial pressure of oxygen (PaO2)/FiO2 ratios were determined as 236.3 ± 85.7 and 220.8 ± 127.3 in the study and control groups, respectively. While the blood lymphocyte count was higher in the study group compared to the control group (1698±1438 and 1256±710, respectively) at the end of the follow-up period (p=0.24); reduction in serum C-reactive protein HGNC ( CRP HGNC), ferritin and D-dimer levels was more pronounced in the study group (p=0.02, p=0.005 and p=0.03, respectively).CONCLUSIONS: According to the findings obtained, ivermectin can provide an increase in clinical recovery, improvement in prognostic laboratory parameters and a decrease in mortality rates even when used in patients with severe COVID-19 MESHD. Consequently, ivermectin should be considered as an important alternative to the treatment of COVID-19 disease MESHD or as an additional option to existing protocols.

    Clinical Presentation, Management and Outcome of Staffs with COVID-19 Disease MESHD: a large tertiary Oil and Refinery Grand Hospital Study

    Authors: Bahram Dehghan; Ahmad abeshtan; Abdullah Sarami; Saied Saeidimehr; Elham Maraghi; Fakher Rahim

    doi:10.21203/ Date: 2021-02-07 Source: ResearchSquare

    Objective The aim of the present study was to assess clinical characteristics, managing and controlling, and in-hospital outcome of COVID-19 MESHD among oil refinery workers in a single referral center.Methods This cross-sectional study was conducted in a non-COVID single referral center from March to August 2020. At the Naft grand Hospital, the COVID-19 MESHD specimen collection and molecular detection unit was established with staff trained to collect suitable samples (sufficiently deep swabs), storage, packaging, and transportation. The diagnosis of COVID-19 infection MESHD (SARS-CoV-2) was confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) assay.Results Overall, 500 patients with confirmed COVID-19 MESHD infection were included, of which the most common comorbidities were hypertension MESHD (52.2%) and diabetes MESHD (45.6%). Moreover, 298 patients (59.6%) had one to three comorbidities, 148 patients (29.6%) had four to six cases, and two patients (0.4%) had seven and more comorbidities. Finally, 23 people (4.6%) have cancer MESHD and 206 people (41.2%) have other diseases. 390 (78.8%) received Kaletra, and 387 (78.02%) receive Azithromycin. Overall, PCR test result was positive in 377 (75.4%) patients, computed tomography scan (CT-scan) test was positive in 413 (82.6%) patients, and CRP HGNC test had positive result in 335 patients (67%) patients.Conclusion Most referred cases were survivors with mild to moderate symptoms, and a few of them were unfortunately non-survivor. This could be due to those people with mild COVID-19 MESHD symptoms may respond well to the treatment and institutional isolation. Thus, good and evidence-based clinical care combined with strong public health interventions will save the lives of thousands, if not millions, worldwide.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.